Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zevra Therapeutics, Inc. (ZVRA)
USD12.64
-0.42 (-3.19%)
US NASDAQ Healthcare Biotechnology
Address
1180 Celebration Boulevard 34747
Celebration, FL, US
Celebration, FL, US
CEO
Neil F. McFarlane
Website
zevra.com
IPO
2015-04-16
CIK 1434647 ISIN US4884452065
Also trades on
NASDAQ Global Select · KMPH (USD)
NASDAQ Global Select · ZVRA (USD)
Description
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.64
-0.42 (-3.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.89
Float Shares
54.58M
Free Float %
92.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.31% | -0.81% | +13.68% | +30.00% | +19.72% | +23.33% | +40.41% | +153.44% | +29.69% | -88.53% | -93.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
12.64
Low
25.00
+97.7%
Consensus
25.50
+101.7%
Median
25.50
+101.7%
High
26.00
+105.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
23.00
+81.9%
|
| Last Year | 4 |
24.25
+91.8%
|
| All Time | 12 |
21.92
+73.4%
|
Quality scores
Altman Z-Score
5.95
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
4 / 5
High
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+350.9% ★ Q1'26: +77.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+159.2% ★ Q1'26: +1,147.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+56.3% Q1'26: +16.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+88.9% ★ Q1'26: +24.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+338.5% ★ Q1'26: +26.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+23.8% Q1'26: +11.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.64× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 7 Rev. Ana. 5 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.84M
est: 16.98M (-24.4%)
|
13.29M
est: 12.88M (+3.1%)
|
28.65M
est: 28.30M (+1.2%)
|
10.16M
est: 11.24M (-9.6%)
|
27.46M
est: 23.69M (+15.9%)
|
23.61M
est: 20.51M (+15.1%)
|
106.47M
est: 100.38M (+6.1%)
|
147.57M
142.10M – 151.05M
+47.0% YoY
|
215.32M
204.50M – 233.23M
+45.9% YoY
|
302.64M
302.64M – 302.64M
+40.6% YoY
|
360.65M
323.98M – 431.27M
+19.2% YoY
|
409.70M
368.03M – 489.91M
+13.6% YoY
|
| EBITDA |
-17.73M
est: -12.51M (-41.7%)
|
-5.43M
est: -9.49M (+42.8%)
|
-7.89M
est: -20.85M (+62.2%)
|
-25.53M
est: -8.28M (-208.2%)
|
-43.54M
est: -11.13M (-291.4%)
|
-76.40M
est: -9.63M (-693.2%)
|
98.71M
est: -47.14M (+309.4%)
|
-69.30M
-70.94M – -66.74M
-47.0% YoY
|
-101.12M
-109.54M – -96.04M
-45.9% YoY
|
-142.13M
-142.13M – -142.13M
-40.6% YoY
|
-169.38M
-202.54M – -152.15M
-19.2% YoY
|
-192.41M
-230.08M – -172.84M
-13.6% YoY
|
| EBIT |
-18.03M
est: -12.61M (-43.0%)
|
-5.70M
est: -9.57M (+40.4%)
|
-8.15M
est: -21.02M (+61.3%)
|
-26.47M
est: -8.35M (-217.1%)
|
-44.55M
est: -11.35M (-292.6%)
|
-82.79M
est: -9.82M (-742.7%)
|
94.66M
est: -48.09M (+296.8%)
|
-70.69M
-72.36M – -68.07M
-47.0% YoY
|
-103.15M
-111.73M – -97.97M
-45.9% YoY
|
-144.98M
-144.98M – -144.98M
-40.6% YoY
|
-172.77M
-206.60M – -155.20M
-19.2% YoY
|
-196.27M
-234.69M – -176.31M
-13.6% YoY
|
| Net Income |
-24.52M
est: -525.41M (+95.3%)
|
-12.76M
est: -127.19M (+90.0%)
|
-8.56M
est: -39.54M (+78.4%)
|
-26.77M
est: -52.65M (+49.1%)
|
-46.05M
est: -103.34M (+55.4%)
|
-105.51M
est: -109.00M (+3.2%)
|
83.23M
est: 71.59M (+16.3%)
|
56.45M
27.15M – 70.30M
-21.2% YoY
|
79.77M
71.35M – 88.18M
+41.3% YoY
|
153.78M
85.57M – 238.34M
+92.8% YoY
|
173.02M
150.14M – 217.05M
+12.5% YoY
|
194.04M
168.39M – 243.43M
+12.2% YoY
|
| SGA |
10.82M
est: 20.31M (-46.8%)
|
7.92M
est: 15.41M (-48.6%)
|
8.70M
est: 33.86M (-74.3%)
|
15.04M
est: 13.45M (+11.8%)
|
35.09M
est: 28.97M (+21.1%)
|
54.87M
est: 25.08M (+118.8%)
|
77.62M
est: 122.75M (-36.8%)
|
180.45M
173.77M – 184.71M
+47.0% YoY
|
263.30M
250.07M – 285.21M
+45.9% YoY
|
370.08M
370.08M – 370.08M
+40.6% YoY
|
441.02M
396.17M – 527.37M
+19.2% YoY
|
500.99M
450.04M – 599.08M
+13.6% YoY
|
| EPS |
-13.23
est: -11.36 (-16.5%)
|
-3.21
est: -2.75 (-16.7%)
|
-2.11
est: -0.86 (-146.8%)
|
-0.78
est: -1.12 (+30.0%)
|
-1.30
est: -1.70 (+23.6%)
|
-2.28
est: -1.89 (-20.4%)
|
1.40
est: 1.25 (+12.0%)
|
1.01
0.47 – 1.23
-19.3% YoY
|
1.40
1.25 – 1.54
+38.7% YoY
|
2.43
1.49 – 4.16
+74.0% YoY
|
3.02
2.62 – 3.79
+24.1% YoY
|
3.39
2.94 – 4.25
+12.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 4/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 4/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
16.93M
OE per share TTM
0.29
Owner's Yield
2.58%
Maintenance CapEx ratio
2.43%
Maint CapEx / Avg PPE
6.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
31
Total invested
27.04M
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Woodline Partners LP | 4.05M | 7.70% | 4.05M | — | 4.05M | — | IA | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
31
-137 vs prev Q
New positions
4
Closed positions
130
Increased
15
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 4.51M +469.9K (+11.6%) | 40.38M +2.0M (+5.2%) | 8.06% +0.686 pp | 0.00% +0.000 pp | USD7.45 +20.3% | 6 qtrs — |
| 2 | WOODLINE PARTNERS LP | 3.45M -25.3K (-0.7%) | 30.92M -2.1M (-6.5%) | 6.17% -0.178 pp | 0.12% -0.036 pp | USD6.56 +36.6% | 8 qtrs — |
| 3 | VANGUARD GROUP INC | 3.31M +221.8K (+7.2%) | 29.61M +291.9K (+1.0%) | 5.91% +0.279 pp | 0.00% +0.000 pp | USD8.31 +7.8% | 20 qtrs — |
| 4 | FMR LLC | 2.39M +758.9K (+46.4%) | 21.45M +5.9M (+38.0%) | 4.28% +1.294 pp | 0.00% +0.000 pp | USD7.59 +18.1% | 16 qtrs — |
| 5 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.77M -200.0K (-10.1%) | 15.88M -2.9M (-15.3%) | 3.17% -0.433 pp | 0.52% -0.126 pp | USD6.35 +41.1% | 10 qtrs — |
| 6 | STATE STREET CORP | 1.48M +55.7K (+3.9%) | 13.29M -286.3K (-2.1%) | 2.65% +0.045 pp | 0.00% +0.000 pp | USD7.39 +21.2% | 19 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.34M +41.3K (+3.2%) | 12.02M -344.4K (-2.8%) | 2.40% +0.024 pp | 0.00% +0.000 pp | USD7.35 +21.9% | 20 qtrs — |
| 8 | MORGAN STANLEY | 1.16M +602.0K (+108.3%) | 10.37M +5.1M (+96.2%) | 2.07% +1.055 pp | 0.00% +0.000 pp | USD8.84 +1.4% | 20 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 1.13M +99.1K (+9.6%) | 10.16M +318.6K (+3.2%) | 2.03% +0.138 pp | 0.00% +0.000 pp | USD8.97 -0.1% | 6 qtrs — |
| 10 | LEGAL & GENERAL GROUP PLC | 1.10M +44.6K (+4.2%) | 9.84M -179.9K (-1.8%) | 1.96% +0.040 pp | 0.00% 0.000 pp | USD8.00 +12.0% | 11 qtrs — |
| 11 | 683 CAPITAL MANAGEMENT, LLC | 905.0K -70.0K (-7.2%) | 8.11M -1.2M (-12.5%) | 1.62% -0.162 pp | 0.35% -0.132 pp | USD6.39 +40.2% | 9 qtrs — |
| 12 | ROYCE & ASSOCIATES LP | 865.8K +174.6K (+25.3%) | 7.76M +1.2M (+18.0%) | 1.55% +0.286 pp | 0.08% +0.013 pp | USD9.40 -4.7% | 2 qtrs — |
| 13 | D. E. SHAW & CO., INC. | 863.7K +137.9K (+19.0%) | 7.74M +836.5K (+12.1%) | 1.54% +0.219 pp | 0.00% +0.000 pp | USD9.25 -3.1% | 5 qtrs — |
| 14 | TUDOR INVESTMENT CORP ET AL | 692.1K +244.2K (+54.5%) | 6.20M +1.9M (+45.6%) | 1.24% +0.419 pp | 0.01% +0.004 pp | USD9.32 -3.9% | 2 qtrs — |
| 15 | MARSHALL WACE, LLP | 669.7K -242.6K (-26.6%) | 6.00M -2.7M (-30.8%) | 1.20% -0.468 pp | 0.01% -0.003 pp | USD9.51 -5.8% | 2 qtrs — |
| 16 | RETIREMENT PLANNING CO OF NEW ENGLAND, INC. | 663.0K +62.2K (+10.4%) | 5.94M +226.9K (+4.0%) | 1.18% +0.088 pp | 2.38% +0.084 pp | USD7.28 +23.1% | 17 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 588.7K -173.1K (-22.7%) | 5.27M -2.0M (-27.2%) | 1.05% -0.338 pp | 0.00% 0.000 pp | USD8.84 +1.4% | 20 qtrs — |
| 18 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 585.1K -64.9K (-10.0%) | 5.24M -939.3K (-15.2%) | 1.05% -0.141 pp | 0.62% -0.144 pp | USD9.03 -0.8% | 3 qtrs — |
| 19 | STONEPINE CAPITAL MANAGEMENT, LLC | 569.1K -240.9K (-29.7%) | 5.10M -2.6M (-33.8%) | 1.02% -0.462 pp | 3.72% -2.540 pp | USD7.37 +21.6% | 6 qtrs — |
| 20 | JANE STREET GROUP, LLC | 563.9K +349.7K (+163.3%) | 5.05M +3.0M (+148.0%) | 1.01% +0.617 pp | 0.00% +0.001 pp | USD8.98 -0.2% | 3 qtrs — |
| 21 | CAPTION MANAGEMENT, LLC | 540.1K +30.0K (+5.9%) | 4.84M -11.6K (-0.2%) | 0.97% +0.034 pp | 0.03% -0.005 pp | USD9.48 -5.5% | 6 qtrs — |
| 22 | SCHRODER INVESTMENT MANAGEMENT GROUP | 506.0K +93.5K (+22.7%) | 4.46M +522.5K (+13.3%) | 0.90% +0.151 pp | 0.00% +0.000 pp | USD8.97 -0.1% | 3 qtrs — |
| 23 | NORTHERN TRUST CORP | 418.1K -21.4K (-4.9%) | 3.75M -433.1K (-10.4%) | 0.75% -0.055 pp | 0.00% 0.000 pp | USD6.99 +28.2% | 20 qtrs — |
| 24 | JPMORGAN CHASE & CO | 412.3K -26.7K (-6.1%) | 3.69M -480.9K (-11.5%) | 0.74% -0.065 pp | 0.00% +0.000 pp | USD9.31 -3.8% | 19 qtrs — |
| 25 | STRATOS WEALTH PARTNERS, LTD. | 409.0K +180.0K (+78.6%) | 3.66M +1.5M (+68.3%) | 0.73% +0.313 pp | 0.04% +0.016 pp | USD8.10 +10.6% | 18 qtrs — |
| 26 | QUBE RESEARCH & TECHNOLOGIES LTD | 356.2K +49.8K (+16.2%) | 3.19M +277.2K (+9.5%) | 0.64% +0.077 pp | 0.00% +0.000 pp | USD9.41 -4.8% | 3 qtrs — |
| 27 | MYSTIC ASSET MANAGEMENT, INC. | 346.5K -125.0 (0.0%) | 3.10M -191.8K (-5.8%) | 0.62% -0.014 pp | 0.70% -0.042 pp | USD6.17 +45.2% | 17 qtrs — |
| 28 | SQUAREPOINT OPS LLC | 317.1K +49.0K (+18.3%) | 2.84M +291.5K (+11.4%) | 0.57% +0.077 pp | 0.00% +0.001 pp | USD9.43 -5.0% | 12 qtrs — |
| 29 | UBS GROUP AG | 285.5K +67.4K (+30.9%) | 2.56M +483.9K (+23.3%) | 0.51% +0.112 pp | 0.00% +0.000 pp | USD8.68 +3.2% | 17 qtrs — |
| 30 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 275.0K -2.0M (-87.6%) | 2.46M -18.7M (-88.4%) | 0.49% -3.570 pp | 0.00% -0.030 pp | USD8.19 +9.4% | 6 qtrs — |
| 31 | TREXQUANT INVESTMENT LP | 209.7K -93.2K (-30.8%) | 1.88M -1.0M (-34.8%) | 0.37% -0.178 pp | 0.02% -0.013 pp | USD9.51 -5.8% | 2 qtrs — |
| 32 | JANNEY MONTGOMERY SCOTT LLC | 202.9K +19.2K (+10.4%) | 1.82M +71.0K (+4.1%) | 0.36% +0.027 pp | 0.00% +0.000 pp | USD8.02 +11.7% | 20 qtrs — |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 197.2K +23.9K (+13.8%) | 1.77M +118.8K (+7.2%) | 0.35% +0.036 pp | 0.00% +0.000 pp | USD8.50 +5.4% | 20 qtrs — |
| 34 | TFG ASSET MANAGEMENT GP LTD | 192.5K +192.5K (+100.0%) | 1.72M +1.7M (+100.0%) | 0.34% +0.344 pp | 0.36% +0.364 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 35 | AQR CAPITAL MANAGEMENT LLC | 181.1K +28.8K (+18.9%) | 1.62M +174.4K (+12.0%) | 0.32% +0.046 pp | 0.00% 0.000 pp | USD9.42 -4.9% | 2 qtrs — |
| 36 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 180.6K +22.9K (+14.5%) | 1.62M +118.0K (+7.9%) | 0.32% +0.035 pp | 0.00% +0.000 pp | USD6.82 +31.4% | 19 qtrs — |
| 37 | KOVACK ADVISORS, INC. | 175.3K +48.0 (+0.0%) | 1.57M -96.0K (-5.8%) | 0.31% -0.007 pp | 0.07% -0.084 pp | USD8.81 +1.7% | 19 qtrs — |
| 38 | BANK OF NEW YORK MELLON CORP | 174.2K +48.3K (+38.4%) | 1.56M +363.8K (+30.4%) | 0.31% +0.082 pp | 0.00% +0.000 pp | USD7.66 +17.0% | 19 qtrs — |
| 39 | WELLINGTON MANAGEMENT GROUP LLP | 170.3K -17.0K (-9.1%) | 1.53M -254.9K (-14.3%) | 0.30% -0.038 pp | 0.00% +0.000 pp | USD7.97 +12.4% | 4 qtrs — |
| 40 | CITADEL ADVISORS LLC | 157.2K +55.1K (+54.0%) | 1.41M +437.5K (+45.1%) | 0.28% +0.095 pp | 0.00% +0.000 pp | USD8.25 +8.6% | 20 qtrs — |
| 41 | DIMENSIONAL FUND ADVISORS LP | 154.5K +154.5K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.28% +0.276 pp | 0.00% +0.000 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 42 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 151.4K +100.4K (+196.6%) | 1.36M +871.3K (+179.5%) | 0.27% +0.177 pp | 0.00% +0.002 pp | USD9.15 -2.1% | 2 qtrs — |
| 43 | ACADIAN ASSET MANAGEMENT LLC | 149.6K +68.1K (+83.4%) | 1.34M +564.0K (+72.9%) | 0.27% +0.119 pp | 0.00% +0.001 pp | USD9.26 -3.2% | 2 qtrs — |
| 44 | BANK OF AMERICA CORP /DE/ | 146.4K -141.7K (-49.2%) | 1.31M -1.4M (-52.1%) | 0.26% -0.264 pp | 0.00% 0.000 pp | USD8.51 +5.3% | 19 qtrs — |
| 45 | NUVEEN, LLC | 143.1K -9.9K (-6.5%) | 1.28M -172.9K (-11.9%) | 0.26% -0.024 pp | 0.00% +0.000 pp | USD7.86 +14.0% | 4 qtrs — |
| 46 | HENNION & WALSH ASSET MANAGEMENT, INC. | 139.6K +139.6K (+100.0%) | 1.25M +1.3M (+100.0%) | 0.25% +0.250 pp | 0.04% +0.043 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 47 | DLD ASSET MANAGEMENT, LP | 120.8K +120.8K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.22% +0.216 pp | 0.08% +0.080 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 48 | JEFFERIES FINANCIAL GROUP INC. | 120.0K +120.0K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.21% +0.215 pp | 0.01% +0.006 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 49 | CITIGROUP INC | 118.7K +101.2K (+577.4%) | 1.06M +896.9K (+538.2%) | 0.21% +0.180 pp | 0.00% +0.000 pp | USD8.77 +2.2% | 19 qtrs — |
| 50 | CREDIT AGRICOLE S A | 106.0K +106.0K (+100.0%) | 949.8K +949.8K (+100.0%) | 0.19% +0.189 pp | 0.00% +0.002 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 51 | BARCLAYS PLC | 100.1K +42.5K (+73.8%) | 897.2K +497.5K (+124.5%) | 0.18% +0.074 pp | 0.00% +0.000 pp | USD8.31 +7.8% | 14 qtrs — |
| 52 | MAN GROUP PLC | 92.3K +58.7K (+174.4%) | 827.4K +507.4K (+158.5%) | 0.17% +0.104 pp | 0.00% +0.001 pp | USD9.16 -2.2% | 4 qtrs — |
| 53 | ARETE WEALTH ADVISORS, LLC | 69.8K -4.5K (-6.1%) | 625.0K -81.0K (-11.5%) | 0.12% -0.011 pp | 0.04% -0.006 pp | USD8.14 +10.1% | 20 qtrs — |
| 54 | RHUMBLINE ADVISERS | 68.3K -9.2K (-11.9%) | 611.8K -125.1K (-17.0%) | 0.12% -0.019 pp | 0.00% 0.000 pp | USD6.05 +48.1% | 11 qtrs — |
| 55 | WELLS FARGO & COMPANY/MN | 67.0K +30.1K (+81.7%) | 599.9K +249.4K (+71.1%) | 0.12% +0.052 pp | 0.00% +0.000 pp | USD8.11 +10.5% | 20 qtrs — |
| 56 | TWO SIGMA INVESTMENTS, LP | 65.6K +65.6K (+100.0%) | 588.1K +588.1K (+100.0%) | 0.12% +0.117 pp | 0.00% +0.001 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 57 | ALLIANCEBERNSTEIN L.P. | 65.2K -5.1K (-7.3%) | 584.1K -84.5K (-12.6%) | 0.12% -0.012 pp | 0.00% +0.000 pp | USD8.03 +11.6% | 7 qtrs — |
| 58 | PROPEL BIO MANAGEMENT, LLC | 63.7K -168.2K (-72.5%) | 570.6K -1.6M (-74.1%) | 0.11% -0.310 pp | 0.49% -1.720 pp | USD7.36 +21.7% | 6 qtrs — |
| 59 | LOS ANGELES CAPITAL MANAGEMENT LLC | 54.5K -4.1K (-7.0%) | 552.2K -4.6K (-0.8%) | 0.10% -0.010 pp | 0.00% +0.000 pp | USD8.81 +1.7% | 3 qtrs — |
| 60 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 56.1K +56.1K (+100.0%) | 502.9K +502.9K (+100.0%) | 0.10% +0.100 pp | 0.11% +0.108 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 61 | CARRET ASSET MANAGEMENT, LLC | 54.0K -3.0K (-5.3%) | 483.8K -58.6K (-10.8%) | 0.10% -0.008 pp | 0.05% -0.007 pp | USD8.19 +9.4% | 4 qtrs — |
| 62 | ENTRYPOINT CAPITAL, LLC | 52.9K +24.0K (+83.1%) | 473.7K +199.1K (+72.5%) | 0.09% +0.042 pp | 0.18% +0.078 pp | USD9.26 -3.2% | 5 qtrs — |
| 63 | DEUTSCHE BANK AG\ | 45.9K +1.9K (+4.4%) | 411.6K -6.9K (-1.6%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD6.48 +38.3% | 10 qtrs — |
| 64 | AQUATIC CAPITAL MANAGEMENT LLC | 45.2K +16.6K (+58.0%) | 404.8K +132.8K (+48.9%) | 0.08% +0.029 pp | 0.01% +0.007 pp | USD8.35 +7.3% | 5 qtrs — |
| 65 | ENGINEERS GATE MANAGER LP | 44.0K +8.4K (+23.4%) | 394.4K +55.3K (+16.3%) | 0.08% +0.014 pp | 0.00% +0.001 pp | USD9.41 -4.8% | 2 qtrs — |
| 66 | SIMPLIFY ASSET MANAGEMENT INC. | 42.4K -104.6K (-71.2%) | 379.6K -1.0M (-72.8%) | 0.08% -0.193 pp | 0.01% -0.020 pp | USD7.28 +23.1% | 6 qtrs — |
| 67 | CAMPBELL & CO INVESTMENT ADVISER LLC | 38.6K +964.0 (+2.6%) | 345.8K -12.1K (-3.4%) | 0.07% +0.000 pp | 0.02% -0.010 pp | USD8.81 +1.7% | 3 qtrs — |
| 68 | FRANKLIN RESOURCES INC | 36.8K -41.0 (-0.1%) | 329.7K -20.6K (-5.9%) | 0.07% -0.002 pp | 0.00% +0.000 pp | USD9.51 -5.8% | 2 qtrs — |
| 69 | SANCTUARY ADVISORS, LLC | 34.5K +5.2K (+18.0%) | 308.8K +30.9K (+11.1%) | 0.06% +0.008 pp | 0.00% +0.000 pp | USD5.37 +66.9% | 7 qtrs — |
| 70 | STONERIDGE INVESTMENT PARTNERS LLC | 32.8K +11.7K (+55.2%) | 294.0K +93.0K (+46.3%) | 0.06% +0.020 pp | 0.20% +0.067 pp | USD9.31 -3.8% | 2 qtrs — |
| 71 | INVESCO LTD. | 32.2K +647.0 (+2.1%) | 288.4K -11.5K (-3.9%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD7.36 +21.7% | 11 qtrs — |
| 72 | PRICE T ROWE ASSOCIATES INC /MD/ | 32.1K +3.6K (+12.8%) | 288.0K +17.0K (+6.3%) | 0.06% +0.005 pp | 0.00% +0.000 pp | USD7.10 +26.2% | 8 qtrs — |
| 73 | IFG ADVISORS, LLC | 29.1K +— (+0.0%) | 260.3K -16.0K (-5.8%) | 0.05% -0.001 pp | 0.04% -0.002 pp | USD5.90 +51.9% | 11 qtrs — |
| 74 | METLIFE INVESTMENT MANAGEMENT, LLC | 27.9K +2.7K (+10.5%) | 249.7K +9.9K (+4.1%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD6.29 +42.4% | 11 qtrs — |
| 75 | WINTON GROUP LTD | 26.1K +13.9K (+114.5%) | 233.8K +118.1K (+102.1%) | 0.05% +0.024 pp | 0.01% +0.004 pp | USD9.22 -2.8% | 2 qtrs — |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 25.9K +962.0 (+3.9%) | 231.7K -5.1K (-2.1%) | 0.05% +0.001 pp | 0.00% +0.000 pp | USD6.02 +48.8% | 7 qtrs — |
| 77 | RAYMOND JAMES FINANCIAL INC | 25.7K +2.3K (+10.1%) | 229.8K +8.2K (+3.7%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD8.40 +6.7% | 5 qtrs — |
| 78 | FOX RUN MANAGEMENT, L.L.C. | 24.7K -6.3K (-20.3%) | 221.5K -73.5K (-24.9%) | 0.04% -0.012 pp | 0.03% -0.012 pp | USD9.26 -3.2% | 3 qtrs — |
| 79 | FEDERATED HERMES, INC. | 23.5K +3.5K (+17.8%) | 210.1K +20.8K (+11.0%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD9.40 -4.7% | 3 qtrs — |
| 80 | INTECH INVESTMENT MANAGEMENT LLC | 20.0K -900.0 (-4.3%) | 179.2K -19.6K (-9.8%) | 0.04% -0.002 pp | 0.00% 0.000 pp | USD7.21 +24.3% | 6 qtrs — |
| 81 | PROFUND ADVISORS LLC | 18.1K +888.0 (+5.2%) | 162.0K -1.5K (-0.9%) | 0.03% +0.001 pp | 0.00% 0.000 pp | USD9.48 -5.5% | 2 qtrs — |
| 82 | VERITION FUND MANAGEMENT LLC | 17.7K -175.8K (-90.9%) | 158.6K -1.7M (-91.4%) | 0.03% -0.322 pp | 0.00% -0.007 pp | USD9.51 -5.8% | 4 qtrs — |
| 83 | POLYMER CAPITAL MANAGEMENT (US) LLC | 17.1K -14.6K (-46.0%) | 153.4K -148.0K (-49.1%) | 0.03% -0.027 pp | 0.02% -0.016 pp | USD9.14 -2.0% | 3 qtrs — |
| 84 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 16.9K -1.8K (-9.5%) | 151.4K -26.1K (-14.7%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD5.46 +64.1% | 11 qtrs — |
| 85 | RAFFERTY ASSET MANAGEMENT, LLC | 15.9K +4.0K (+34.0%) | 142.6K +29.7K (+26.3%) | 0.03% +0.007 pp | 0.00% +0.000 pp | USD9.37 -4.4% | 2 qtrs — |
| 86 | CITY STATE BANK | 15.5K +— (+0.0%) | 138.7K -8.5K (-5.8%) | 0.03% -0.001 pp | 0.04% -0.005 pp | USD8.32 +7.7% | 17 qtrs — |
| 87 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 15.0K +15.0K (+100.0%) | 134.4K +134.4K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 88 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 15.0K +— (+0.0%) | 134.1K -8.2K (-5.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD8.63 +3.8% | 5 qtrs — |
| 89 | QUANTINNO CAPITAL MANAGEMENT LP | 15.0K +447.0 (+3.1%) | 134.0K -4.0K (-2.9%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD9.00 -0.4% | 3 qtrs — |
| 90 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 14.9K -115.9K (-88.6%) | 133.4K -1.1M (-89.3%) | 0.03% -0.212 pp | 0.00% -0.004 pp | USD9.51 -5.8% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 85 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 1.16% | 899.4K | 2.82% |
| 2 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.14% | 5.38M | 0.35% |
| 3 | Inspire Fidelis Multi Factor ETF FDLS | 1.01% | 2.33M | 0.66% |
| 4 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.89% | 3.28M | 0.30% |
| 5 | Invesco Dorsey Wright Healthcare Momentum ETF PTH | 0.88% | 1.48M | 0.72% |
| 6 | Janus Henderson Small/Mid Cap Growth Alpha ETF JSMD | 0.81% | 8.73M | 0.30% |
| 7 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.57% | 126.3K | 0.20% |
| 8 | Burney U.S. Factor Rotation ETF BRNY | 0.46% | 2.14M | 0.79% |
| 9 | Burney U.S. Equity Select ETF BRES | 0.46% | 2.83M | 0.79% |
| 10 | Invesco Dorsey Wright SmallCap Momentum ETF DWAS | 0.39% | 1.84M | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.06
Neutral
Ratio by volume
2.54
Bullish
Buys
19
Sells
18
Shares acquired
1.45M
Shares disposed
569.4K
Cash buys
—
Cash sales
8.00
Net activity
+879,637
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | Bode John B | Director | M-Exempt | A | Common Stock | 39,200 | 4.89 | 191.7K | 123,400 | D | ↗ |
| 2026-03-18 | Renz Justin A | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 9.55 | 2.87M | 300,000 | D | ↗ |
| 2026-02-09 | McFarlane Neil F. | Director / Officer | S-Sale | D | Common Stock | 14,625 | 8.56 | 125.2K | 387,225 | D | ↗ |
| 2026-02-07 | McFarlane Neil F. | Director / Officer | M-Exempt | A | Common Stock | 37,500 | 0.00 | — | 401,850 | D | ↗ |
| 2026-02-03 | Schafer Joshua | Officer | S-Sale | D | Common Stock | 10,500 | 9.19 | 96.5K | 62,278 | D | ↗ |
| 2026-02-03 | Sangiovanni Timothy J. | Officer | S-Sale | D | Common Stock | 3,000 | 9.18 | 27.5K | 29,590 | D | ↗ |
| 2026-02-02 | McFarlane Neil F. | Director / Officer | S-Sale | D | Common Stock | 91,000 | 9.38 | 853.4K | 364,350 | D | ↗ |
| 2026-01-31 | Schafer Joshua | Officer | M-Exempt | D | Restricted Stock Unit | 35,334 | 0.00 | — | 35,333 | D | ↗ |
| 2026-01-31 | Sangiovanni Timothy J. | Officer | M-Exempt | D | Restricted Stock Unit | 11,666 | 0.00 | — | 11,668 | D | ↗ |
| 2026-01-31 | McFarlane Neil F. | Director / Officer | M-Exempt | A | Common Stock | 233,334 | 0.00 | — | 455,350 | D | ↗ |
| 2026-01-30 | Thompson Rahsaan | Officer | M-Exempt | A | Common Stock | 11,333 | 0.00 | — | 53,999 | D | ↗ |
| 2026-01-30 | Schafer Joshua | Officer | M-Exempt | A | Common Stock | 11,333 | 0.00 | — | 40,819 | D | ↗ |
| 2026-01-30 | Sangiovanni Timothy J. | Officer | M-Exempt | D | Restricted Stock Unit | 6,333 | 0.00 | — | 12,667 | D | ↗ |
| 2026-01-30 | Quartel Adrian W | Officer | M-Exempt | D | Restricted Stock Unit | 11,333 | 0.00 | — | 22,667 | D | ↗ |
| 2026-01-29 | Thompson Rahsaan | Officer | A-Award | A | Restricted Stock Unit | 37,500 | 0.00 | — | 37,500 | D | ↗ |
| 2026-01-29 | Schafer Joshua | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 8.86 | 664.5K | 75,000 | D | ↗ |
| 2026-01-29 | Quartel Adrian W | Officer | A-Award | A | Restricted Stock Unit | 37,500 | 0.00 | — | 37,500 | D | ↗ |
| 2026-01-29 | McFarlane Neil F. | Director / Officer | A-Award | A | Restricted Stock Unit | 125,000 | 0.00 | — | 125,000 | D | ↗ |
| 2025-12-31 | Clifton R. LaDuane | Other | M-Exempt | A | Common Stock | 140,667 | 0.00 | — | 192,028 | D | ↗ |
| 2025-12-02 | Secor Alicia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-10 | McFarlane Neil F. | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 0.00 | — | 241,516 | D | ↗ |
| 2025-09-12 | Shih Alvin | Director | P-Purchase | A | Common Stock | 20,000 | 7.89 | 157.8K | 20,000 | D | ↗ |
| 2025-09-12 | FAVORITO TAMARA A | Director | P-Purchase | A | Common Stock | 3,175 | 7.79 | 24.7K | 3,894 | D | ↗ |
| 2025-08-19 | Bode John B | Director | P-Purchase | A | Common Stock | 5,000 | 9.17 | 45.8K | 45,000 | D | ↗ |
| 2025-06-26 | Thompson Rahsaan | Officer | S-Sale | D | Common Stock | 24,000 | 9.21 | 221.0K | 42,666 | D | ↗ |
| 2025-06-21 | Thompson Rahsaan | Officer | M-Exempt | D | Restricted Stock Unit | 66,666 | 0.00 | — | 133,334 | D | ↗ |
| 2025-05-29 | Watton Corey Michael | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | Shih Alvin | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | FAVORITO TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | DIXON WENDY L | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | Calder Douglas W | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | Bode John B | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-05-29 | Anderson Thomas | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 8.62 | 258.6K | 30,000 | D | ↗ |
| 2025-03-28 | Watton Corey Michael | Director | P-Purchase | A | Common Stock | 300 | 7.84 | 2.4K | 1,800 | D | ↗ |
| 2025-03-19 | Bode John B | Director | P-Purchase | A | Common Stock | 10,000 | 7.96 | 79.6K | 40,000 | D | ↗ |
| 2025-02-14 | McFarlane Neil F. | Director / Officer | S-Sale | D | Common Stock | 30,544 | 8.05 | 246.0K | 191,516 | D | ↗ |
| 2025-02-13 | Schafer Joshua | Officer | S-Sale | D | Common Stock | 10,500 | 7.86 | 82.5K | 29,486 | D | ↗ |
| 2025-02-13 | Sangiovanni Timothy J. | Officer | S-Sale | D | Common Stock | 3,000 | 7.86 | 23.6K | 16,341 | D | ↗ |
| 2025-02-13 | McFarlane Neil F. | Director / Officer | S-Sale | D | Common Stock | 61,273 | 7.86 | 481.4K | 222,060 | D | ↗ |
| 2025-02-13 | Clifton R. LaDuane | Officer | S-Sale | D | Common Stock | 11,000 | 7.86 | 86.5K | 51,361 | D | ↗ |
| 2025-02-07 | McFarlane Neil F. | Director / Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 7.77 | 1.75M | 225,000 | D | ↗ |
| 2025-01-31 | Schafer Joshua | Officer | M-Exempt | D | Restricted Stock Unit | 35,333 | 0.00 | — | 70,667 | D | ↗ |
| 2025-01-31 | Sangiovanni Timothy J. | Officer | M-Exempt | D | Restricted Stock Unit | 11,666 | 0.00 | — | 23,334 | D | ↗ |
| 2025-01-31 | McFarlane Neil F. | Director / Officer | M-Exempt | D | Restricted Stock Unit | 233,333 | 0.00 | — | 466,667 | D | ↗ |
| 2025-01-31 | Clifton R. LaDuane | Officer | M-Exempt | A | Common Stock | 43,333 | 0.00 | — | 62,361 | D | ↗ |
| 2025-01-30 | Thompson Rahsaan | Officer | A-Award | A | Restricted Stock Unit | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2025-01-30 | Schafer Joshua | Officer | A-Award | A | Restricted Stock Unit | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2025-01-30 | Sangiovanni Timothy J. | Officer | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-01-30 | Quartel Adrian W | Officer | A-Award | A | Restricted Stock Unit | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2025-01-30 | Clifton R. LaDuane | Officer | A-Award | A | Restricted Stock Unit | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2024-12-06 | Quartel Adrian W | Officer | — | — | Stock Option (right to buy) | 300,000 | 6.42 | 1.93M | 0 | D | ↗ |
| 2024-10-11 | Watton Corey Michael | Director | P-Purchase | A | Common Stock | 500 | 7.92 | 4.0K | 1,500 | D | ↗ |
| 2024-07-17 | Clifton R. LaDuane | Officer | P-Purchase | A | Common Stock | 2,000 | 6.77 | 13.5K | 18,469 | — | ↗ |
| 2024-07-16 | Anderson Thomas | Director | P-Purchase | A | Common Stock | 10,000 | 6.81 | 68.1K | 20,000 | — | ↗ |
| 2024-07-12 | Bode John B | Director | P-Purchase | A | Common Stock | 10,000 | 5.87 | 58.7K | 30,000 | — | ↗ |
| 2024-06-21 | Thompson Rahsaan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-13 | Watton Corey Michael | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-05-13 | Shih Alvin | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-05-13 | FAVORITO TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 49,200 | 4.89 | 240.6K | 49,200 | — | ↗ |
| 2024-05-13 | DIXON WENDY L | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-05-13 | Calder Douglas W | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-05-13 | Bode John B | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-05-13 | Anderson Thomas | Director | A-Award | A | Stock Option (right to buy) | 39,200 | 4.89 | 191.7K | 39,200 | — | ↗ |
| 2024-01-31 | Schafer Joshua | Officer | A-Award | A | Restricted Stock Unit | 106,000 | 0.00 | — | 106,000 | — | ↗ |
| 2024-01-31 | Sangiovanni Timothy J. | Officer | A-Award | A | Restricted Stock Unit | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2024-01-31 | Mickle Christal M M | Officer | A-Award | A | Restricted Stock Unit | 77,000 | 0.00 | — | 77,000 | — | ↗ |
| 2024-01-31 | McFarlane Neil F. | Director / Officer | A-Award | A | Restricted Stock Unit | 700,000 | 0.00 | — | 700,000 | — | ↗ |
| 2024-01-31 | Guenther Sven | Officer | A-Award | A | Restricted Stock Unit | 79,000 | 0.00 | — | 79,000 | — | ↗ |
| 2024-01-31 | Clifton R. LaDuane | Officer | A-Award | A | Restricted Stock Unit | 130,000 | 0.00 | — | 130,000 | — | ↗ |
| 2024-01-20 | Shih Alvin | Director | A-Award | A | Stock Option (right to buy) | 58,800 | 5.72 | 336.3K | 58,800 | — | ↗ |
Executive team
Top executives
EBIT / Employee
1.60M
Shares Outstanding
59.11M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | R. LaDuane Clifton , MBA, CPA Former Chief Financial Officer and Treasurer | 477.3K | — | 1.26M | 1.12M | — | 967.0K | 3.82M | 62.21% | ↗ |
| 2 | 2025 | Neil F. McFarlane President, Chief Executive Officer and Director | 729.2K | — | 874.1K | 1.75M | 419.0K | 11.6K | 3.78M | 69.34% | ↗ |
| 3 | 2025 | Rahsaan W. Thompson Chief Legal Officer, Secretary and Compliance Officer | 466.7K | 50.0K | 272.7K | 545.4K | 178.6K | 58.1K | 1.57M | 52.06% | ↗ |
| 4 | 2024 | Neil F. McFarlane President, Chief Executive Officer and Director | 700.0K | 150.0K | 4.02M | — | 455.7K | 31.4K | 5.36M | 75.03% | ↗ |
| 5 | 2024 | R. LaDuane Clifton , MBA, CPA Former Chief Financial Officer and Treasurer | 460.9K | — | 746.2K | — | 201.3K | 41.9K | 1.45M | 51.45% | ↗ |
| 6 | 2023 | Richard W. Pascoe Former Chief Executive Officer and Director | 273.6K | — | — | 3.47M | — | 379.5K | 4.12M | 84.16% | ↗ |
| 7 | 2023 | Travis Mickle, Ph.D. Former President, Chief Executive Officer and Director | 186.5K | — | 2.20M | 354.1K | — | 848.0K | 3.59M | 71.21% | ↗ |
| 8 | 2023 | Neil F. McFarlane President, Chief Executive Officer and Director | 157.5K | 200.0K | 735.4K | 2.21M | 105.5K | 40.7K | 3.45M | 85.38% | ↗ |
| 9 | 2023 | R. LaDuane Clifton, MBA, CPA Chief Financial Officer, Secretary and Treasurer | 446.5K | — | — | 1.60M | 197.1K | 14.8K | 2.26M | 70.91% | ↗ |
| 10 | 2023 | Joshua Schafer Chief Commercial Officer and Executive Vice President, Business Development | 452.3K | 100.0K | — | 1.05M | 200.5K | 13.2K | 1.81M | 57.84% | ↗ |
| 11 | 2023 | Christal M.M. Mickle, M.A. Former Interim Chief Executive Officer | 435.5K | — | — | 1.05M | 173.3K | 13.6K | 1.67M | 62.73% | ↗ |
| 12 | 2022 | Travis Mickle, Ph.D. Former President, Chief Executive Officer and Director | 590.2K | — | — | 1.52M | 282.7K | 12.2K | 2.40M | 63.13% | ↗ |
| 13 | 2022 | Richard W. Pascoe Former Chief Executive Officer and Director | 422.9K | — | — | 722.9K | 202.9K | 12.2K | 1.36M | 53.12% | ↗ |
| 14 | 2022 | R. LaDuane Clifton, MBA, CPA Chief Financial Officer, Secretary and Treasurer | 411.0K | — | — | 474.8K | 138.4K | 13.8K | 1.04M | 45.74% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Neil F. McFarlane | President, Chief Executive Officer & Director | 1M | male |
| Joshua Schafer | Chief Commercial Officer | 766.1K | male |
| Rahsaan W. Thompson | Chief Legal Officer, Secretary & Compliance Officer | 753.3K | male |
| Adrian Quartel FFPM | Chief Medical Officer | 705.1K | — |
| Justin A. Renz | Chief Financial Officer & Treasurer | 704.1K | male |
| Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality | — | male |
| Christopher Lauderback | Senior Vice President of Manufacturing | — | — |
| Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications | — | female |
| Alison Peters | Chief People Officer | — | female |
| Tanya Hayden | Senior Vice President & Chief of Staff | — | female |
| Timothy J. Sangiovanni | Senior VP of Finance & Corporate Controller | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ZVRA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
